Abstract: An eustachian tube (ET) drug eluting stent includes a plurality of longitudinal spars with spring-like elements between each of the plurality of longitudinal spars, creating smooth arcs between each of the plurality of longitudinal spars while minimizing impediment of mucociliary flow. The combination of the plurality of longitudinal spars with spring-like elements are configured to enter into the ET uncompressed.

Abstract: An eustachian tube (ET) drug eluting stent includes a plurality of longitudinal spars with spring-like elements between each of the plurality of longitudinal spars, creating smooth arcs between each of the plurality of longitudinal spars while minimizing impediment of mucociliary flow. The combination of the plurality of longitudinal spars with spring-like elements are configured to enter into the ET uncompressed.

Abstract: An eustachian tube (ET) drug eluting stent includes a plurality of longitudinal spars with spring-like elements between each of the plurality of longitudinal spars, creating smooth arcs between each of the plurality of longitudinal spars while minimizing impediment of mucociliary flow. The combination of the plurality of longitudinal spars with spring-like elements are configured to enter into the ET uncompressed.

Abstract: A nasal irrigation solution (or composition) for pre- and post-operation sinus surgery and for use as a daily nasal cleanser. The composition, which may be in a powder form, may include lactated ringers with xylitol. This composition may be mixed with sterile water prior to nasal irrigation.

Abstract: A nasal irrigation solution (or composition) for pre- and post-operation sinus surgery and for use as a daily nasal cleanser. The composition, which may be in a powder form, may include lactated ringers with xylitol. This composition may be mixed with sterile water prior to nasal irrigation.

Abstract: The present invention provides a method and formulation for treating and preventing asteatosis or “dry ear” symptoms and inflammation. The method of the present invention comprises topically applying to the ear canal a semi-viscous diglycerin and butylene glycol polyhydroxy liquid formulation including hydrocortisone, a natural product anti-irritant, a wound healing agent, and an anti-inflammatory agent, stabilized with a cationic surfactant and a nonionic surfactant.

Abstract: The present invention provides a method and formulation for treating and preventing asteatosis or “dry ear” symptoms and inflammation. The method of the present invention comprises topically applying to the ear canal a semi-viscous diglycerin and butylene glycol polyhydroxy liquid formulation including hydrocortisone, a natural product anti-irritant, a wound healing agent, and an anti-inflammatory agent, stabilized with a cationic surfactant and a nonionic surfactant.

Abstract: A method of treating diseases and conditions associated with dry ear comprising topically applying to the ear canal of a subject that is suffering therefrom a liquid composition comprising an anti-irritant agent, a wound healing agent; and an anti-inflammatory agent dissolved in a polyhydroxy liquid solvent.

Abstract: A method of treating diseases and conditions associated with dry ear comprising topically applying to the ear canal of a subject that is suffering therefrom a liquid composition comprising an anti-irritant agent, a wound healing agent; and an anti-inflammatory agent dissolved in a polyhydroxy liquid solvent.

Abstract: A method of treating diseases and conditions associated with dry ear comprising topically applying to the ear canal of a subject that is suffering therefrom a liquid composition comprising an anti-irritant agent, a wound healing agent; and an anti-inflammatory agent dissolved in a polyhydroxy liquid solvent.